Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/11000/28837
Agonistas Serotoninérgicos: ¿Indicados en la Enfermedad Mental?
Título : Agonistas Serotoninérgicos: ¿Indicados en la Enfermedad Mental? |
Autor : Navarro López, Mario |
Tutor: García Fernández, Lorena |
Editor : Universidad Miguel Hernández de Elche |
Departamento: Departamentos de la UMH::Medicina Clínica |
Fecha de publicación: 2022-05-24 |
URI : https://hdl.handle.net/11000/28837 |
Resumen :
Las enfermedades mentales suponen una causa de discapacidad cada vez más
prevalente en nuestro medio. Ante los pequeños o moderados efectos terapéuticos
que ofrecen los vigentes tratamientos psiquiátricos, es primordial buscar nuevos
modelos de tratamiento que garanticen una mejor cobertura terapéu... Ver más
Mental illnesses are an increasingly prevalent cause of disability in our environment.
Given the small or moderate therapeutic effects offered by current psychiatric
treatments, it is essential to seek new treatment models that guarantee better
therapeutic coverage of the mental health of our population. The new therapeutic
model highlights the influence that a transformation of our psychology has on the cure
of mental illnesses; and experiences with serotonergic agonists facilitate a greater
interaction of the subjects with their unconscious mind, facilitating psychotherapeutic
intervention. Research with serotonergic agonists shows very promising results in
terms of neuronal effects, promoting neurogenesis, neuroplasticity, functional changes
similar to those provided by mindfulness training, and reduction of inflammation at the
neuronal level. Preliminary clinical trials and meta-analyses on serotonergic agonists
show very favorable data regarding response to treatment even after a single dose of
these. All this leads us to show interest in the study with DMT, a very promising
serotonergic agonist for mental health care.
|
Palabras clave/Materias: Enfermedades mentales DMT 5-MeO-DMT Ayahuasca Psychotria viridis Banisteriopsis Caapi Psilocibina |
Área de conocimiento : CDU: Ciencias aplicadas: Medicina |
Tipo de documento : info:eu-repo/semantics/bachelorThesis |
Derechos de acceso: info:eu-repo/semantics/openAccess |
Aparece en las colecciones: TFG- Medicina
|
La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.